RVAC and University of Pennsylvania to develop mRNA vaccines
Pharmaceutical Technology
MARCH 20, 2023
The partnership will focus on developing potential new vaccines to treat certain selected autoimmune indications, as well as food allergies. RVAC Medicines chief scientific officer Dr Jason Zhang said: “We are very glad to work with Dr Weissman on potential mRNA treatment approaches for a broad spectrum of allergy and autoimmune diseases.
Let's personalize your content